Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Sylvia Gutz"'
Autor:
Adrien Dixmier, Denis Moro-Sibilot, Andreas Gröschel, Fabrice Barlesi, Sylvia Gutz, Maurice Pérol, Christian Schumann, John R. Penrod, Didier Debieuvre, Charles A. Butts, Dorothee Reynaud, D Waldenberger, Khalid Lakhdari, Filippa Pettersson, Martin Sebastian, Catherine Labbé, Clarisse Audigier-Valette, Victoria Allan, Rosalyn A. Juergens, Ariadna Juarez-Garcia
Publikováno v:
Journal of Clinical Oncology. 38:e21714-e21714
e21714 Background: Data from clinical studies demonstrate a long-term survival benefit of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC) patients with overall survival (OS) at two-years of 27%, however real-world data are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12df7eb578dcfe13c385d6c87c60beb0
https://doi.org/10.1200/jco.2020.38.15_suppl.e21714
https://doi.org/10.1200/jco.2020.38.15_suppl.e21714
Autor:
Nikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero, Jan Stratmann, Richard Riedel, Monica Schaefer, Jürgen Alt, Sylvia Gütz, Daniel C. Christoph, Eckart Laack, Martin Faehling, Richard Fischer, Klaus Fenchel, Sebastian Haen, Lukas Heukamp, Christian Schulz, Frank Griesinger
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Introduction: We report on the results of the German early access program (EAP) with the third-generation ALK- and ROS1-inhibitor lorlatinib. Patients and Methods: Patients with documented treatment failure of all approved ALK/ROS1-specific therapies
Externí odkaz:
https://doaj.org/article/f7e788036eba4a14b4cfaa74838a764b